Vyriad, a gene therapy company based in Rochester, has raised $85 million to support its new VV-169 cancer treatment which ...
The first healthy volunteers have been dosed in an early clinical trial testing NRG5051, a disease-modifying therapy for ALS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback